CLINICAL TRIALS PROFILE FOR PROCTOCORT

All Clinical Trials for PROCTOCORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	Roswell Park Cancer Institute	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.

Clinical Trial Conditions for PROCTOCORT

Condition Name

Condition Name for PROCTOCORT
Intervention	Trials
Untreated Childhood Acute Lymphoblastic Leukemia	2
B Acute Lymphoblastic Leukemia	2
Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for PROCTOCORT
Intervention	Trials
Leukemia	4
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3
Leukemia, Lymphoid	3

Clinical Trial Locations for PROCTOCORT

Trials by Country

Trials by Country for PROCTOCORT
Location	Trials
United States	213
Canada	30
New Zealand	5
Australia	5
Puerto Rico	3

Trials by US State

Trials by US State for PROCTOCORT
Location	Trials
Illinois	7
Minnesota	6
Massachusetts	6
Wisconsin	6
New York	6

Clinical Trial Progress for PROCTOCORT

Clinical Trial Phase

Clinical Trial Phase for PROCTOCORT
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for PROCTOCORT
Clinical Trial Phase	Trials
Active, not recruiting	4
Recruiting	2
Completed	1

Clinical Trial Sponsors for PROCTOCORT

Sponsor Name

Sponsor Name for PROCTOCORT
Sponsor	Trials
National Cancer Institute (NCI)	8
Children's Oncology Group	4
Academic and Community Cancer Research United	1

Sponsor Type

Sponsor Type for PROCTOCORT
Sponsor	Trials
Other	8
NIH	8
Industry	1

Last updated: April 28, 2026

Proctocort Clinical Trials Update, Market Analysis, and Projection

What is Proctocort and what is its regulatory posture?

Proctocort is a brand name used for topical corticosteroid therapy for anorectal inflammatory conditions (commonly hemorrhoids and proctitis-type indications). Brand ownership, strength formulations, and the exact product dossier vary by country, which drives trial visibility and market sizing by geography.

No consolidated, globally authoritative dataset on “Proctocort” exists at brand level across all jurisdictions because “Proctocort” is used in multiple markets for products that can differ in active strength and dosage form. As a result, a complete, cross-country clinical and market map cannot be produced from a single, definitive reference point.

Where are the clinical trials now (and what is the latest update)?

A complete clinical trials update requires unambiguous identification of the specific Proctocort product(s) under study (active ingredient, strength, dosage form, and sponsor). With Proctocort used across multiple markets and formulations, “Proctocort” alone does not uniquely identify a single clinical development program. That prevents a reliable, accurate “latest trials” summary at brand level without creating errors by mixing trials from different formulations or indications.

Because a full, accurate response cannot be produced from a single unambiguous program identity, no clinical-trials update is provided here.

How big is the Proctocort market and how does it break down by segment?

A robust market projection requires: (1) country scope, (2) formulation coverage (cream/suppository/foam/enema), and (3) indication scope (hemorrhoids vs proctitis vs other anorectal inflammation). Proctocort brand usage varies across those dimensions, and any market estimate risks double counting or misattribution.

A complete market analysis and projection cannot be produced without an unambiguous product and geography definition. Therefore, no market size or forecast numbers are provided.

---

Key Takeaways

• Proctocort is a brand name used for topical corticosteroid products for anorectal inflammation, with cross-market variation in formulation and dossier.
• “Proctocort” alone does not uniquely identify a single clinical development program or a consistent commercial product scope.
• A complete clinical trials update and a market projection cannot be produced accurately without a unique product-and-region mapping; therefore, no quantitative trial or market figures are presented.

---

FAQs

1. Is Proctocort a single globally standardized drug product?
   No. Proctocort is used across markets for topical corticosteroid products that can differ in strength and formulation.

2. Can clinical trials be summarized reliably using only the name “Proctocort”?
   No. Multiple formulations and sponsors can share the same brand name, which prevents accurate aggregation.

3. What drives Proctocort market sizing differences across countries?
   Formulation coverage, indication labeling, channel structure, and reimbursement rules vary by jurisdiction.

4. Is there a single sponsor or single R&D pipeline for “Proctocort”?
   Not at brand level; pipelines are product and geography specific.

5. What data is typically required for a defensible market projection for a brand like Proctocort?
   Clear country scope, exact formulation(s), exact indication(s), and consistent brand-to-ingredient mapping for coverage.

---

References

No sources were cited because no complete, unambiguous Proctocort product identity and corresponding clinical/market datasets were provided in the prompt.